Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany.
Greiner W, Lehmann K, Earnshaw S, Bug C, Sabatowski R (2006)
Eur J Health Econ 7(4): 290-296.
Zeitschriftenaufsatz
| Veröffentlicht | Englisch
Download
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
Autor*in
Greiner, WolfgangUniBi;
Lehmann, K;
Earnshaw, S;
Bug, C;
Sabatowski, R
Einrichtung
Abstract / Bemerkung
We carried out a cost-effectiveness evaluation of transdermal fentanyl compared to three other widely used opioids: transdermal buprenorphine, sustained-release morphine, and controlled-release oxycodone from a third-party-payers perspective. A decision analytic model with data from a structured database search and from panel data and assumptions was used to derive both cost and utility results. Probabilistic sensitivity analysis was performed to ensure the findings. Transdermal fentanyl patients gain more quality adjusted life-days or quality-adjusted life-years per euro. The incremental cost per quality-adjusted life-year is 1,625.65 euro for transdermal fentanyl compared to sustained-release morphine and 1,003.03 euro compared to CO, and it is cost-saving compared to transdermal buprenorphine (-203.38 euro per patient). Transdermal fentanyl is thus cost-effective compared to both sustained-release morphine and CO and dominant compared to transdermal buprenorphine in the treatment of adults with nonmalignant moderate to severe chronic pain.
Erscheinungsjahr
2006
Zeitschriftentitel
Eur J Health Econ
Band
7
Ausgabe
4
Seite(n)
290-296
ISSN
1618-7598
eISSN
1618-7601
Page URI
https://pub.uni-bielefeld.de/record/1665896
Zitieren
Greiner W, Lehmann K, Earnshaw S, Bug C, Sabatowski R. Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany. Eur J Health Econ. 2006;7(4):290-296.
Greiner, W., Lehmann, K., Earnshaw, S., Bug, C., & Sabatowski, R. (2006). Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany. Eur J Health Econ, 7(4), 290-296. https://doi.org/10.1007/s10198-006-0376-8
Greiner, Wolfgang, Lehmann, K, Earnshaw, S, Bug, C, and Sabatowski, R. 2006. “Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany.”. Eur J Health Econ 7 (4): 290-296.
Greiner, W., Lehmann, K., Earnshaw, S., Bug, C., and Sabatowski, R. (2006). Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany. Eur J Health Econ 7, 290-296.
Greiner, W., et al., 2006. Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany. Eur J Health Econ, 7(4), p 290-296.
W. Greiner, et al., “Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany.”, Eur J Health Econ, vol. 7, 2006, pp. 290-296.
Greiner, W., Lehmann, K., Earnshaw, S., Bug, C., Sabatowski, R.: Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany. Eur J Health Econ. 7, 290-296 (2006).
Greiner, Wolfgang, Lehmann, K, Earnshaw, S, Bug, C, and Sabatowski, R. “Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany.”. Eur J Health Econ 7.4 (2006): 290-296.
Daten bereitgestellt von European Bioinformatics Institute (EBI)
14 Zitationen in Europe PMC
Daten bereitgestellt von Europe PubMed Central.
A Cost-Effectiveness Model for Adjunctive Smoked Cannabis in the Treatment of Chronic Neuropathic Pain.
Tyree GA, Sarkar R, Bellows BK, Ellis RJ, Atkinson JH, Marcotte TD, Wallace MS, Grant I, Shi Y, Murphy JD, Grelotti DJ., Cannabis Cannabinoid Res 4(1), 2019
PMID: 30944870
Tyree GA, Sarkar R, Bellows BK, Ellis RJ, Atkinson JH, Marcotte TD, Wallace MS, Grant I, Shi Y, Murphy JD, Grelotti DJ., Cannabis Cannabinoid Res 4(1), 2019
PMID: 30944870
Addressing the barriers related with opioid therapy for management of chronic pain in India.
Dureja GP, Jain PN, Joshi M, Saxena A, Das G, Ahdal J, Narang P., Pain Manag 7(4), 2017
PMID: 28699380
Dureja GP, Jain PN, Joshi M, Saxena A, Das G, Ahdal J, Narang P., Pain Manag 7(4), 2017
PMID: 28699380
Economic evaluation in chronic pain: a systematic review and de novo flexible economic model.
Sullivan W, Hirst M, Beard S, Gladwell D, Fagnani F, López Bastida J, Phillips C, Dunlop WC., Eur J Health Econ 17(6), 2016
PMID: 26377997
Sullivan W, Hirst M, Beard S, Gladwell D, Fagnani F, López Bastida J, Phillips C, Dunlop WC., Eur J Health Econ 17(6), 2016
PMID: 26377997
Clinical simulation model of long-acting opioids for treatment of chronic non-cancer pain in the United States.
Neil N, Merchant S, Provenzano D, Ogden K, Mody SH., J Med Econ 16(2), 2013
PMID: 23216013
Neil N, Merchant S, Provenzano D, Ogden K, Mody SH., J Med Econ 16(2), 2013
PMID: 23216013
The cost-effectiveness of duloxetine in chronic low back pain: a US private payer perspective.
Wielage RC, Bansal M, Andrews JS, Wohlreich MM, Klein RW, Happich M., Value Health 16(2), 2013
PMID: 23538186
Wielage RC, Bansal M, Andrews JS, Wohlreich MM, Klein RW, Happich M., Value Health 16(2), 2013
PMID: 23538186
Budget impact analysis of tapentadol extended release for the treatment of moderate to severe chronic noncancer pain.
Merchant S, Noe LL, Howe A, Duff S, Gricar J, Ogden K, Mody SH., Clin Ther 35(5), 2013
PMID: 23587608
Merchant S, Noe LL, Howe A, Duff S, Gricar J, Ogden K, Mody SH., Clin Ther 35(5), 2013
PMID: 23587608
Cost-effectiveness of duloxetine in chronic low back pain: a Quebec societal perspective.
Wielage R, Bansal M, Wilson K, Klein R, Happich M., Spine (Phila Pa 1976) 38(11), 2013
PMID: 23250234
Wielage R, Bansal M, Wilson K, Klein R, Happich M., Spine (Phila Pa 1976) 38(11), 2013
PMID: 23250234
Cost-utility analysis of duloxetine in osteoarthritis: a US private payer perspective.
Wielage RC, Bansal M, Andrews JS, Klein RW, Happich M., Appl Health Econ Health Policy 11(3), 2013
PMID: 23616247
Wielage RC, Bansal M, Andrews JS, Klein RW, Happich M., Appl Health Econ Health Policy 11(3), 2013
PMID: 23616247
Pharmacoeconomic impact of adverse events of long-term opioid treatment for the management of persistent pain.
Annemans L., Clin Drug Investig 31(2), 2011
PMID: 21067250
Annemans L., Clin Drug Investig 31(2), 2011
PMID: 21067250
Cost-effectiveness of strong opioids focussing on the long-term effects of opioid-related fractures: a model approach.
Hass B, Lungershausen J, Hertel N, Poulsen Nautrup B, Kotowa W, Liedgens H., Eur J Health Econ 10(3), 2009
PMID: 19101743
Hass B, Lungershausen J, Hertel N, Poulsen Nautrup B, Kotowa W, Liedgens H., Eur J Health Econ 10(3), 2009
PMID: 19101743
Nausea and vomiting side effects with opioid analgesics during treatment of chronic pain: mechanisms, implications, and management options.
Porreca F, Ossipov MH., Pain Med 10(4), 2009
PMID: 19302436
Porreca F, Ossipov MH., Pain Med 10(4), 2009
PMID: 19302436
Cost-effectiveness analysis of a lidocaine 5% medicated plaster compared with gabapentin and pregabalin for treating postherpetic neuralgia: a german perspective.
Liedgens H, Hertel N, Gabriel A, Nuijten M, Dakin H, Mitchell S, Nautrup BP., Clin Drug Investig 28(9), 2008
PMID: 18666805
Liedgens H, Hertel N, Gabriel A, Nuijten M, Dakin H, Mitchell S, Nautrup BP., Clin Drug Investig 28(9), 2008
PMID: 18666805
Cost-effectiveness of a lidocaine 5% medicated plaster relative to gabapentin for postherpetic neuralgia in the United Kingdom.
Dakin H, Nuijten M, Liedgens H, Nautrup BP., Clin Ther 29(7), 2007
PMID: 17825701
Dakin H, Nuijten M, Liedgens H, Nautrup BP., Clin Ther 29(7), 2007
PMID: 17825701
Modeling the economic and health consequences of managing chronic osteoarthritis pain with opioids in Germany: comparison of extended-release oxycodone and OROS hydromorphone.
Ward A, Bozkaya D, Fleischmann J, Dubois D, Sabatowski R, Caro JJ., Curr Med Res Opin 23(10), 2007
PMID: 17697453
Ward A, Bozkaya D, Fleischmann J, Dubois D, Sabatowski R, Caro JJ., Curr Med Res Opin 23(10), 2007
PMID: 17697453
37 References
Daten bereitgestellt von Europe PubMed Central.
Patient-reported utilization patterns of fentanyl transdermal system and oxycodone hydrochloride controlled-release among patients with chronic nonmalignant pain.
Ackerman SJ, Mordin M, Reblando J, Xu X, Schein J, Vallow S, Brennan M., J Manag Care Pharm 9(3), 2003
PMID: 14613465
Ackerman SJ, Mordin M, Reblando J, Xu X, Schein J, Vallow S, Brennan M., J Manag Care Pharm 9(3), 2003
PMID: 14613465
Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain.
Allan L, Hays H, Jensen NH, de Waroux BL, Bolt M, Donald R, Kalso E., BMJ 322(7295), 2001
PMID: 11348910
Allan L, Hays H, Jensen NH, de Waroux BL, Bolt M, Donald R, Kalso E., BMJ 322(7295), 2001
PMID: 11348910
AUTHOR UNKNOWN, 0
Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability.
Barbieri M, Drummond M, Willke R, Chancellor J, Jolain B, Towse A., Value Health 8(1), 2005
PMID: 15841890
Barbieri M, Drummond M, Willke R, Chancellor J, Jolain B, Towse A., Value Health 8(1), 2005
PMID: 15841890
AUTHOR UNKNOWN, 0
AUTHOR UNKNOWN, 0
Treatment of osteoarthritis pain with controlled release oxycodone or fixed combination oxycodone plus acetaminophen added to nonsteroidal antiinflammatory drugs: a double blind, randomized, multicenter, placebo controlled trial.
Caldwell JR, Hale ME, Boyd RE, Hague JM, Iwan T, Shi M, Lacouture PG., J. Rheumatol. 26(4), 1999
PMID: 10229408
Caldwell JR, Hale ME, Boyd RE, Hague JM, Iwan T, Shi M, Lacouture PG., J. Rheumatol. 26(4), 1999
PMID: 10229408
Efficacy and safety of a once-daily morphine formulation in chronic, moderate-to-severe osteoarthritis pain: results from a randomized, placebo-controlled, double-blind trial and an open-label extension trial.
Caldwell JR, Rapoport RJ, Davis JC, Offenberg HL, Marker HW, Roth SH, Yuan W, Eliot L, Babul N, Lynch PM., J Pain Symptom Manage 23(4), 2002
PMID: 11997197
Caldwell JR, Rapoport RJ, Davis JC, Offenberg HL, Marker HW, Roth SH, Yuan W, Eliot L, Babul N, Lynch PM., J Pain Symptom Manage 23(4), 2002
PMID: 11997197
Economic impact of low dose polyethylene glycol 3350 plus electrolytes compared with lactulose in the management of idiopathic constipation in the UK.
Christie AH, Culbert P, Guest JF., Pharmacoeconomics 20(1), 2002
PMID: 11817992
Christie AH, Culbert P, Guest JF., Pharmacoeconomics 20(1), 2002
PMID: 11817992
Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain.
Clark AJ, Ahmedzai SH, Allan LG, Camacho F, Horbay GL, Richarz U, Simpson K., Curr Med Res Opin 20(9), 2004
PMID: 15383190
Clark AJ, Ahmedzai SH, Allan LG, Camacho F, Horbay GL, Richarz U, Simpson K., Curr Med Res Opin 20(9), 2004
PMID: 15383190
A cost-utility analysis of the home parenteral nutrition program at Toronto General Hospital: 1970-1982.
Detsky AS, McLaughlin JR, Abrams HB, Whittaker JS, Whitwell J, L'Abbe K, Jeejeebhoy KN., JPEN J Parenter Enteral Nutr 10(1), 1986
PMID: 3080625
Detsky AS, McLaughlin JR, Abrams HB, Whittaker JS, Whitwell J, L'Abbe K, Jeejeebhoy KN., JPEN J Parenter Enteral Nutr 10(1), 1986
PMID: 3080625
A one year health economic model comparing transdermal fentanyl with sustained-release morphine in the treatment of chronic noncancer pain.
Frei A, Andersen S, Hole P, Jensen NH., J Pain Palliat Care Pharmacother 17(2), 2003
PMID: 14649386
Frei A, Andersen S, Hole P, Jensen NH., J Pain Palliat Care Pharmacother 17(2), 2003
PMID: 14649386
Predicting Quality of Well-being scores from the SF-36: results from the Beaver Dam Health Outcomes Study.
Fryback DG, Lawrence WF, Martin PA, Klein R, Klein BE., Med Decis Making 17(1), 1997
PMID: 8994146
Fryback DG, Lawrence WF, Martin PA, Klein R, Klein BE., Med Decis Making 17(1), 1997
PMID: 8994146
Patient utilities in chronic musculoskeletal pain: how useful is the standard gamble method?
Goossens ME, Vlaeyen JW, Rutten-van Molken MP, van der Linden SM., Pain 80(1-2), 1999
PMID: 10204750
Goossens ME, Vlaeyen JW, Rutten-van Molken MP, van der Linden SM., Pain 80(1-2), 1999
PMID: 10204750
Cost analysis of palliative care for terminally ill cancer patients in the UK after switching from weak to strong opioids. Palliative Care Advisory Committee.
Guest JF, Hart WM, Cookson RF., Pharmacoeconomics 14(3), 1998
PMID: 10186467
Guest JF, Hart WM, Cookson RF., Pharmacoeconomics 14(3), 1998
PMID: 10186467
Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
Haentjens P, De Groote K, Annemans L., Arch Orthop Trauma Surg 124(8), 2004
PMID: 15365714
Haentjens P, De Groote K, Annemans L., Arch Orthop Trauma Surg 124(8), 2004
PMID: 15365714
Efficacy and safety of controlled-release versus immediate-release oxycodone: randomized, double-blind evaluation in patients with chronic back pain.
Hale ME, Fleischmann R, Salzman R, Wild J, Iwan T, Swanton RE, Kaiko RF, Lacouture PG., Clin J Pain 15(3), 1999
PMID: 10524470
Hale ME, Fleischmann R, Salzman R, Wild J, Iwan T, Swanton RE, Kaiko RF, Lacouture PG., Clin J Pain 15(3), 1999
PMID: 10524470
Prioritising elective care: a cost utility analysis of orthopaedics in the north west of England.
James M, St Leger S, Rowsell KV., J Epidemiol Community Health 50(2), 1996
PMID: 8762386
James M, St Leger S, Rowsell KV., J Epidemiol Community Health 50(2), 1996
PMID: 8762386
Recommendations for using opioids in chronic non-cancer pain.
Kalso E, Allan L, Dellemijn PL, Faura CC, Ilias WK, Jensen TS, Perrot S, Plaghki LH, Zenz M., Eur J Pain 7(5), 2003
PMID: 12935789
Kalso E, Allan L, Dellemijn PL, Faura CC, Ilias WK, Jensen TS, Perrot S, Plaghki LH, Zenz M., Eur J Pain 7(5), 2003
PMID: 12935789
Costs of opioid therapy for chronic nonmalignant pain in Germany: an economic model comparing transdermal fentanyl (Durogesic) with controlled-release morphine.
Radbruch L, Lehmann K, Gockel HH, Neighbors D, Nuyts G., Eur J Health Econ 3(2), 2002
PMID: 24577592
Radbruch L, Lehmann K, Gockel HH, Neighbors D, Nuyts G., Eur J Health Econ 3(2), 2002
PMID: 24577592
Maier, Dtsch Arztebl 99(), 2002
Cost-effectiveness of lumbar discectomy for the treatment of herniated intervertebral disc.
Malter AD, Larson EB, Urban N, Deyo RA., Spine 21(9), 1996
PMID: 8724089
Malter AD, Larson EB, Urban N, Deyo RA., Spine 21(9), 1996
PMID: 8724089
Evaluation of long-term efficacy and safety of transdermal fentanyl in the treatment of chronic noncancer pain.
Milligan K, Lanteri-Minet M, Borchert K, Helmers H, Donald R, Kress HG, Adriaensen H, Moulin D, Jarvimaki V, Haazen L., J Pain 2(4), 2001
PMID: 14622817
Milligan K, Lanteri-Minet M, Borchert K, Helmers H, Donald R, Kress HG, Adriaensen H, Moulin D, Jarvimaki V, Haazen L., J Pain 2(4), 2001
PMID: 14622817
Economic evaluation of the fentanyl transdermal system for the treatment of chronic moderate to severe pain.
Neighbors DM, Bell TJ, Wilson J, Dodd SL., J Pain Symptom Manage 21(2), 2001
PMID: 11226764
Neighbors DM, Bell TJ, Wilson J, Dodd SL., J Pain Symptom Manage 21(2), 2001
PMID: 11226764
Responsible prescribing of opioids for the management of chronic pain.
Nicholson B., Drugs 63(1), 2003
PMID: 12487620
Nicholson B., Drugs 63(1), 2003
PMID: 12487620
AUTHOR UNKNOWN, 0
Constipation and the use of laxatives: a comparison between transdermal fentanyl and oral morphine.
Radbruch L, Sabatowski R, Loick G, Kulbe C, Kasper M, Grond S, Lehmann KA., Palliat Med 14(2), 2000
PMID: 10829145
Radbruch L, Sabatowski R, Loick G, Kulbe C, Kasper M, Grond S, Lehmann KA., Palliat Med 14(2), 2000
PMID: 10829145
Around-the-clock, controlled-release oxycodone therapy for osteoarthritis-related pain: placebo-controlled trial and long-term evaluation.
Roth SH, Fleischmann RM, Burch FX, Dietz F, Bockow B, Rapoport RJ, Rutstein J, Lacouture PG., Arch. Intern. Med. 160(6), 2000
PMID: 10737286
Roth SH, Fleischmann RM, Burch FX, Dietz F, Bockow B, Rapoport RJ, Rutstein J, Lacouture PG., Arch. Intern. Med. 160(6), 2000
PMID: 10737286
Can a controlled-release oral dose form of oxycodone be used as readily as an immediate-release form for the purpose of titrating to stable pain control?
Salzman RT, Roberts MS, Wild J, Fabian C, Reder RF, Goldenheim PD., J Pain Symptom Manage 18(4), 1999
PMID: 10534967
Salzman RT, Roberts MS, Wild J, Fabian C, Reder RF, Goldenheim PD., J Pain Symptom Manage 18(4), 1999
PMID: 10534967
Utility assessments of opioid treatment for chronic pain.
Schmier JK, Palmer CS, Flood EM, Gourlay G., Pain Med 3(3), 2002
PMID: 15099257
Schmier JK, Palmer CS, Flood EM, Gourlay G., Pain Med 3(3), 2002
PMID: 15099257
AUTHOR UNKNOWN, 0
The impact of nausea and vomiting on women: a burden of early pregnancy.
Smith C, Crowther C, Beilby J, Dandeaux J., Aust N Z J Obstet Gynaecol 40(4), 2000
PMID: 11194422
Smith C, Crowther C, Beilby J, Dandeaux J., Aust N Z J Obstet Gynaecol 40(4), 2000
PMID: 11194422
Health-related quality of life and hand eczema--a comparison of two instruments, including factor analysis.
Wallenhammar LM, Nyfjall M, Lindberg M, Meding B., J. Invest. Dermatol. 122(6), 2004
PMID: 15175027
Wallenhammar LM, Nyfjall M, Lindberg M, Meding B., J. Invest. Dermatol. 122(6), 2004
PMID: 15175027
Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia.
Watson CP, Babul N., Neurology 50(6), 1998
PMID: 9633737
Watson CP, Babul N., Neurology 50(6), 1998
PMID: 9633737
World, Cancer pain relief and palliative care(), 1990
AUTHOR UNKNOWN, 0
World, Cancer pain relief and palliative care(), 2004
Export
Markieren/ Markierung löschen
Markierte Publikationen
Quellen
PMID: 16983521
PubMed | Europe PMC
Suchen in
Google Scholar